Cargando…

HIV-1 elite controllers: an immunovirological review and clinical perspectives

HIV type 1 (HIV-1) elite controllers (ECs) represent a rare group of individuals with an ability to maintain an undetectable HIV-1 viral load overtime in the absence of previous antiretroviral therapy. The mechanisms associated with this paradigm remain not clearly defined. However, loss of virologi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gebara, Nour Y, El Kamari, Vanessa, Rizk, Nesrine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mediscript Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816117/
https://www.ncbi.nlm.nih.gov/pubmed/31700663
_version_ 1783463316989935616
author Gebara, Nour Y
El Kamari, Vanessa
Rizk, Nesrine
author_facet Gebara, Nour Y
El Kamari, Vanessa
Rizk, Nesrine
author_sort Gebara, Nour Y
collection PubMed
description HIV type 1 (HIV-1) elite controllers (ECs) represent a rare group of individuals with an ability to maintain an undetectable HIV-1 viral load overtime in the absence of previous antiretroviral therapy. The mechanisms associated with this paradigm remain not clearly defined. However, loss of virological control, morbidity and mortality persist in these individuals, such as progress to AIDS-defining conditions together with persistent high rate of immune activation. Further insight into potential therapeutic options is therefore warranted. In this review, we discuss recent data on the type of immune responses understood to be associated with chronic virological control, the potential for disease progression and therapeutic options in ECs.
format Online
Article
Text
id pubmed-6816117
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Mediscript Ltd
record_format MEDLINE/PubMed
spelling pubmed-68161172019-11-07 HIV-1 elite controllers: an immunovirological review and clinical perspectives Gebara, Nour Y El Kamari, Vanessa Rizk, Nesrine J Virus Erad Review HIV type 1 (HIV-1) elite controllers (ECs) represent a rare group of individuals with an ability to maintain an undetectable HIV-1 viral load overtime in the absence of previous antiretroviral therapy. The mechanisms associated with this paradigm remain not clearly defined. However, loss of virological control, morbidity and mortality persist in these individuals, such as progress to AIDS-defining conditions together with persistent high rate of immune activation. Further insight into potential therapeutic options is therefore warranted. In this review, we discuss recent data on the type of immune responses understood to be associated with chronic virological control, the potential for disease progression and therapeutic options in ECs. Mediscript Ltd 2019-09-18 /pmc/articles/PMC6816117/ /pubmed/31700663 Text en © 2019 The Authors. Journal of Virus Eradication published by Mediscript Ltd http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article published under the terms of a Creative Commons License.
spellingShingle Review
Gebara, Nour Y
El Kamari, Vanessa
Rizk, Nesrine
HIV-1 elite controllers: an immunovirological review and clinical perspectives
title HIV-1 elite controllers: an immunovirological review and clinical perspectives
title_full HIV-1 elite controllers: an immunovirological review and clinical perspectives
title_fullStr HIV-1 elite controllers: an immunovirological review and clinical perspectives
title_full_unstemmed HIV-1 elite controllers: an immunovirological review and clinical perspectives
title_short HIV-1 elite controllers: an immunovirological review and clinical perspectives
title_sort hiv-1 elite controllers: an immunovirological review and clinical perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816117/
https://www.ncbi.nlm.nih.gov/pubmed/31700663
work_keys_str_mv AT gebaranoury hiv1elitecontrollersanimmunovirologicalreviewandclinicalperspectives
AT elkamarivanessa hiv1elitecontrollersanimmunovirologicalreviewandclinicalperspectives
AT rizknesrine hiv1elitecontrollersanimmunovirologicalreviewandclinicalperspectives